Maria Elena Gasperini, Director of Sustainability Life Sciences, Jacobs discuses the ways in which the biopharma industry can build a sustainable future in our latest EPM Online Insight.
Biocon Biologics Limited have announced a long -term commercial collaboration with Eris Lifesciences to expand patient access to its portfolio of Metabolics, Oncology, and Critical Care products in India.
Mike Ludlow, Market Development Manager, Life Sciences; Element Materials Technology provides an assessment of single use systems for biopharmaceutical production and highlights the need for regulatory alignment.
Jimin Kim, Senior CDO Business Strategist at Samsung Biologics, lays out the challenges of successfully progressing complex biologics from clinic to commercialisation.
EPM Editor Jai McIntosh recently caught up with Campbell Bunce, Chief Scientific Officer and Cambridge Site Head at Abzena to discuss Abzena’s ThioBridge technology.
John Cardone, Marketing Manager, Custom Antibodies, Bio-Rad Laboratories explores Monitoring Antibody Drug Safety and Efficacy in Preclinical and Clinical Development in our latest EPM insight.
Campbell Bunce, Chief Scientific Officer and Cambridge Site Head at Abzena looks at how ADCs are being integrated with the capacity to modulate the immune system and how this marks a progressive shift in the fight against cancer.
Professor Afzal R Mohammed, Professor of Pharmaceutics at Aston University and advisor to Max Bio+, explores two promising advancements being explored that could revolutionise biological drug delivery: liquid-based delivery and inhalation.
This article explores how starting materials, specifically producer cell lines and the design of transfer plasmids, affect the quality attributes of AAV vectors.
In this article, Ross Errington, Head of Drug Product Development at Recipharm, explores the growth of the biosimilar market and its role in driving the demand for biologic redevelopment, focusing on the move towards inhaled biologics as a solution.
The biopharma industry has made minor strides toward improved resilience, but it’s not enough to meet future global demand for novel therapeutics. However, Ludovi Brellier, shows how to get there.
